Adjuvant chemotherapy and radiotherapy in the treatment of nonsmall cell lung cancer (NSCLC)

Journal of Thoracic Disease

Volumn 5, Issue SUPPL.4, 2013, Pages

  Zaric, Bojan ^a   Stojsic, Vladimir ^a   Tepavac, Aleksandar ^a   Sarcev, Tatjana ^a   Zarogoulidis, Paul ^b,c   Darwiche, Kaid ^c   Tsakiridis, Kosmas ^d   Karapantzos, Ilias ^d   Kesisis, Georgios ^d   Kougioumtzi, Ioanna ^e   Katsikogiannis, Nikolaos ^e   Machairiotis, Nikolaos ^e   Stylianaki, Aikaterini ^e   Foroulis, Christophoros N ^f   Zarogoulidis, Konstantinos ^b   Perin, Branislav ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c RUHRLANDKLINIK   (Germany)

^d Saint Luke Private Hospital   (Greece)

^e UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^f AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Adjuvant therapy; Chemotherapy; Non small cell lung cancer (NSCLC); Radiotherapy

Indexed keywords

BETA TUBULIN; BETA TUBULIN III; CARBOPLATIN; CISPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MITOMYCIN; NAVELBINE; PACLITAXEL; PROTEIN MSH2; UFT; UNCLASSIFIED DRUG; VINDESINE;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DISEASE SEVERITY; GENERAL ASPECTS OF DISEASE; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT IDENTIFICATION; POSTOPERATIVE CARE; POSTOPERATIVE RADIOTHERAPY; PRACTICE GUIDELINE; RADIATION DOSE; RADIATION INJURY; RECURRENCE FREE SURVIVAL; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL MARGIN; SURVIVAL RATE; THREE DIMENSIONAL CONFORMAL RADIATION THERAPY;

EID: 84901495853     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.05.16     Document Type: Review

References (46)

1. GLOBOCAN 2008. (Available online: http://globocan.iarc.fr/factsheets/ cancers/lung.asp)
2. Zuccato JA, Ellis PM. Improving referral of patients for consideration of adjuvant hemotherapy after surgical resection of lung cancer. Curr Oncol 2012;19:e422-7.
3. Hotta K, Matsuo K, Ueoka H, et al. Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled Trials. J Clin Oncol 2004;22:3860-7.
4. Pisters KM, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007;25:5506-18.
5. Tsuboi M, Ohira T, Saji H, et al. The Present Status of Postoperative Adjuvant Chemotherapy for Completely Resected Non-Small Cell Lung Cancer. Ann Thorac Cardiovasc Surg 2007;13:73-7.
6. Crinò L, Weder W, van Meerbeeck J, et al. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v103-15
7. Available online: http://www.nccn.org/professionals/physician_gls/pdf/ nscl.pdf
8. Chemotherapy in non-small cell lung cancer: a meta-analysis using update data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
9. Scagliotti GV, Fossati R, Torri V, et al. Adjuvant Lung Project Italy/ European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453-61.
10. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173-82.
11. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA nonsmall- cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:1217-22.
12. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
13. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010;28:35-42.
14. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
15. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IBIIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27.
16. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin with observation in stage Ib non-small-cell ling cancer: CALBG 9633 with the Cancer and Leukemia group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-51.
17. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-21.
18. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin aveluation: A pooled analysis by the LACE collaborative group. J Clin Oncol 2008;26:3552-59.
19. Bonomi M, Pilotto S, Milella M, et al. Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res 2011;30:115.
20. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in nonsmall- cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
21. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small- cell lung cancer. J Clin Oncol 2007;25:5240-47.
22. Reiman T, Lai R, Veillard AS, et al. Cross-validation study of class III betatubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 2012;23:86-93.
23. Gomez DR, Komaki R. Postoperative Radiation Therapy for Non-Small Cell Lung Cancer and Thymic Malignancies. Cancers 2012;4: 307-22.
24. Saynak M, Higginson DS, Morris DE, et al. Current status of postoperative radiation for non-small-cell lung cancer. Semin Radiat Oncol 2010;20:192-200.
25. El-Sherif A, Fernando HC, Santos R, et al. Margin and local recurrence after sublobar resection of non-small cell lung cancer. Ann Surg Oncol 2007;14:2400-5.
26. Sawabata N, Maeda H, Matsumura A, et al. Clinical implications of the margin cytology findings and margin/tumor size ratio in patients who underwent pulmonary excision for peripheral non-small cell lung cancer. Surg Today 2012;42:238-44.
27. Tomaszek SC, Kim Y, Cassivi SD, et al. Bronchial resection margin length and clinical outcome in non-small cell lung cancer. Eur J Cardiothorac Surg 2011;40:1151-6.
28. Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006;24:2998-3006.
29. Rescigno J. Use of postoperative radiotherapy for node-positive non-smallcell lung cancer. Clin Lung Cancer 2002;4:35-44.
30. Bogart JA, Aronowitz JN. Localized non-small cell lung cancer: adjuvant radiotherapy in the era of effective systemic therapy. Clin Cancer Res 2005;11:5004s-5010s.
31. National Comprehensive Cancer Network Guidelines. Available online: http://www.nccn.org/(accessed on 3 January 2012) 32. Le Péchoux C. Role of Postoperative Radiotherapy in Resected Non- Small Cell Lung Cancer: A Reassessment Based on New Data. Oncologist 2011;16:672-681.
32. Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: Definitive results of a phase III randomized trial. Radiother Oncol 2002;62:11-9.
33. Stephens RJ, Girling DJ, Bleehen NM, et al. Medical Research Council Lung Cancer Working Party. The role of post-operative radiotherapy in non-small-cell lung cancer: A multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Br J Cancer 1996;74:632-9.
34. Dautzenberg B, Arriagada R, Chammard AB, et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer 1999;86:265-73.
35. Feng QF, Wang M, Wang LJ, et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: A randomized trial. Int J Radiat Oncol Biol Phys 2000;47:925-9.
36. Keller SM, Adak S, Wagner H, et al. Eastern Cooperative Oncology Group. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med 2000;343:1217-22.
37. Bradley JD, Paulus R, Graham MV. Radiation Therapy Oncology Group. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: Promising long-term results of the Radiation Therapy Oncology Group- RTOG 9705. J Clin Oncol 2005;23:3480-7.
38. Feigenberg SJ, Hanlon AL, Langer C, et al. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. J Thorac Oncol 2007;2:287-92.
39. Machtay M, Lee JH, Shrager JB, et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol 2001;19:3912-7.
40. Krupitskaya Y, Loo BW Jr. Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer. Curr Treat Options Oncol 2008;9:343-56.
41. Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007;68:94-102.
42. Korreman SS, Juhler-Nøttrup T, Persson GF, et al. The role of image guidance in respiratory gated radiotherapy. Acta Oncol 2008;47:1390-6.
43. Adams MJ, Hardenbergh PH, Constine LS, et al. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003;45:55-75.
44. Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010;76:S77-85.
45. Machtay M, Lee JH, Shrager JB, et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol 2001;19:3912-7.
46. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010;76:S70-6.M.RAMYA